Cargando…

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

BACKGROUND: Patisiran, an RNA interference therapeutic, has demonstrated robust reduction of wild-type and mutant transthyretin protein and was able to improve polyneuropathy and quality of life following 18 months of treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Teresa, Adams, David, Conceição, Isabel, Waddington-Cruz, Márcia, Schmidt, Hartmut H., Buades, Juan, Campistol, Josep, Berk, John L., Polydefkis, Michael, Wang, Jing Jing, Chen, Jihong, Sweetser, Marianne T., Gollob, Jared, Suhr, Ole B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341568/ https://www.ncbi.nlm.nih.gov/pubmed/32641071 http://dx.doi.org/10.1186/s13023-020-01399-4

Ejemplares similares

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2019)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2020)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
por: Suhr, Ole B, et al.
Publicado: (2015)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Modified Technique of Ex-PRESS(®) Filtration Device Combined with a Scleral Pocket for Hereditary Transthyretin Amyloidosis (hATTR) Secondary Open-Angle Glaucoma
por: Vieira, Rita, et al.
Publicado: (2023)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis
por: Connolly, Mark P., et al.
Publicado: (2019)

Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015)

Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)
por: Adams, David, et al.
Publicado: (2015)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
por: Steinebrei, Maximilian, et al.
Publicado: (2023)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Allele Specific Expression of the Transthyretin Gene in Swedish Patients with Hereditary Transthyretin Amyloidosis (ATTR V30M) Is Similar between the Two Alleles
por: Norgren, Nina, et al.
Publicado: (2012)

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
por: Obici, Laura, et al.
Publicado: (2016)

Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
por: Hsu, Hui-Ching, et al.
Publicado: (2017)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis
por: Ihse, Elisabet, et al.
Publicado: (2010)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers
por: Luigetti, Marco, et al.
Publicado: (2020)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)
por: Nakase, Taku, et al.
Publicado: (2019)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis
por: Schmidt, Matthias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dc8691159cuvlreln11d8tcb8n